Aligos Therapeutics, Inc. financial data

Symbol
ALGS on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 555% % 31%
Debt-to-equity 41% % -76%
Return On Equity -28% % 92%
Return On Assets -20% % 85%
Operating Margin -4025% % -63%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 6,178,230 shares 60%
Entity Public Float $19,900,000 USD -49%
Common Stock, Value, Issued $9,000 USD 12%
Weighted Average Number of Shares Outstanding, Basic 9,884,955 shares 58%
Weighted Average Number of Shares Outstanding, Diluted 9,884,955 shares 58%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $2,186,000 USD -39%
Research and Development Expense $69,453,000 USD -1.2%
General and Administrative Expense $20,718,000 USD -9.3%
Operating Income (Loss) $87,985,000 USD 1.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $23,879,000 USD 82%
Income Tax Expense (Benefit) $314,000 USD -5.1%
Net Income (Loss) Attributable to Parent $24,193,000 USD 82%
Earnings Per Share, Basic -2.45 USD/shares 88%
Earnings Per Share, Diluted -2.45 USD/shares 88%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $18,303,000 USD -51%
Cash, Cash Equivalents, and Short-term Investments $77,800,000 USD 37%
Other Assets, Current $4,908,000 USD -3.6%
Assets, Current $82,862,000 USD 33%
Property, Plant and Equipment, Net $1,867,000 USD -21%
Operating Lease, Right-of-Use Asset $3,089,000 USD -38%
Other Assets, Noncurrent $715,000 USD 14%
Assets $88,533,000 USD 26%
Accounts Payable, Current $3,982,000 USD 55%
Employee-related Liabilities, Current $7,464,000 USD 17%
Accrued Liabilities, Current $13,526,000 USD -13%
Liabilities, Current $21,233,000 USD -2.3%
Operating Lease, Liability, Noncurrent $1,525,000 USD -68%
Liabilities $34,988,000 USD -65%
Accumulated Other Comprehensive Income (Loss), Net of Tax $468,000 USD 3.8%
Retained Earnings (Accumulated Deficit) $642,201,000 USD -3.9%
Stockholders' Equity Attributable to Parent $53,545,000 USD
Liabilities and Equity $88,533,000 USD 26%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 115,800,000 shares 457%
Common Stock, Shares, Issued 6,178,230 shares 60%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18,413,000 USD -50%
Deferred Tax Assets, Valuation Allowance $81,284,000 USD 44%
Deferred Tax Assets, Gross $82,333,000 USD 41%
Operating Lease, Liability $5,105,000 USD -38%
Depreciation $930,000 USD -9.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $24,176,000 USD 82%
Lessee, Operating Lease, Liability, to be Paid $5,416,000 USD -40%
Property, Plant and Equipment, Gross $14,579,000 USD 3.1%
Operating Lease, Liability, Current $3,580,000 USD 4.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,415,000 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,827,000 USD 4.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.0883 pure -0.79%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $311,000 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year Three $174,000 USD -88%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $1,446,000 USD 88%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,049,000 USD -40%
Share-based Payment Arrangement, Expense $5,044,000 USD -40%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%